At a glance
ClinicalIndex Comparison Record- ✓Age 5 to 39 years at time of irradiation
- ✓Planned for CSI with or without boost dose and/or systemic chemotherapy
- ✓Informed consent or assent obtained
- ✕Prior re-irradiation
- ✕Prior exposure to memantine
- ✕Unable to undergo Wechsler test
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06275035Phase 3RecruitingMonitorUpdated 14mo ago · Completion was 5mo agoMemantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)
In Brief
A Phase 3 clinical trial evaluating Memantine Oral Tablet for Neurocognitive Dysfunction. Currently recruiting, targeting 101 participants across 1 site.
Signals
Detailed Summary
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.
Study Details
Timeline
Interventions
Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy